Sponsored

Exploring Tumor Treating Fields Therapy

May 2nd 2024

Examining Current & Potential Targets for Treating EGFR-Mutated Non-Small Cell Lung Cancer

April 29th 2024

PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse

April 25th 2024

Thomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.

The Impact of CAR T Cell Therapy on Managing R/R LBCL

April 17th 2024

CAR T cell therapies have shown remarkable clinical success in difficult-to-treat blood cancers. Read one oncologist’s perspective on what current CAR T therapies may offer patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including at earlier points in their disease journey.

Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell Lymphoma

January 24th 2024

Many people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.

It’s Time to Address Patient Needs: The Changing Landscape of Colorectal Cancer Treatment

January 8th 2024

Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial

December 5th 2023

SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.

Biomarker Testing and Targeted Therapy in NSCLC: Review and Update (Podcast)

November 27th 2023

Expert Derek Lyle, MD, provides an in-depth overview of biomarker testing and targeted therapy in the current landscape of non–small cell lung cancer management.

Biomarker Testing and Targeted Therapy in NSCLC: Review and Update

November 14th 2023

Expert Derek Lyle, MD, provides an in-depth overview of biomarker testing and targeted therapy in the current landscape of non–small cell lung cancer management.

Responding to Resistance in Lung Cancer

October 25th 2023

Non-Hodgkin’s Lymphoma: New Medicines that Address Patient Needs

August 14th 2023

Krish Patel, MD, discusses the latest advances in the treatment of non-Hodgkin’s lymphoma and how fixed-duration treatment options can improve the overall patient experience.

An Individualized Approach to Treating Advanced RCC

July 31st 2023

Grounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.

Recognizing Appropriate Patients for an Antibody-Drug Conjugate: Case Studies in Bladder Cancer

July 24th 2023

Bispecific Targeting CD3 and BCMA Reflect Expanding Options in Multiple Myeloma

July 12th 2023

Bispecific antibodies targeting BCMA have shown efficacy in relapsed refractory multiple myeloma, including bispecifics targeting BCMA x CD3.

Extending Overall Survival in Patients with Advanced Urothelial Carcinoma

July 3rd 2023

The Evolving Advanced RCC Treatment Landscape

June 26th 2023

Researcher and clinician, Dr. Thomas Hutson reflects on the modern patient journey and shares his experience treating people with advanced RCC. Through the years, the advanced RCC treatment landscape has evolved significantly. In this two-part series brought to you by Eisai Inc., hear from oncologist Thomas Hutson, DO as he reflects on best practices for evaluating today’s treatment options.

Health Equity Isn't a Theme, It's a Long-term Commitment

May 30th 2023

Important Considerations for Biomarker Testing in NSCLC at Key Points in Treatment Journey

May 26th 2023

The biomarker testing landscape has evolved over the years, affecting how oncologists approach lung cancer.

Bringing Precision Medicine to Community Oncology is Going to Require Bigger Thinking

May 23rd 2023

Extended Follow-up Analysis of First-Line Treatment for Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma

April 28th 2023